Chinese pharmaceutical companies struggle to compete in the rapidly expanding global weight-loss drug market

As Goldman Sachs projects the global weight-loss drug market will exceed $100 billion by 2030, Chinese domestic pharmaceutical enterprises face intense pressure to develop and commercialize competitive obesity medications. Current solutions fail because most Chinese pharma companies lack the clinical trial infrastructure, regulatory expertise, and international distribution networks needed to compete with established players like Novo Nordisk and Eli Lilly in this lucrative market.